Big pharma earnings preview: what to expect from GSK and AstraZeneca Q1 results
Britain’s two largest drug makers both unveil their first quarter results on Wednesday, with investors eager to an update on how the Covid-19 crisis impacted the pairs performance.
GlaxoSmithKline (GSK) and AstraZeneca both unveil their first quarter (Q1) results on Wednesday, with investors keen to see the impact of the Covid-19 crisis on their financial performance.
AstraZeneca is looking to increase its total revenue by a ‘high single-digit to a low double-digit percentage’ and its core earnings per share (EPS) is forecast to increase by a ‘mid- to high-teens percentage’, according to its previous guidance.
GSK is expecting adjusted EPS to decline by -1% to -4% CER and is targeting a dividend pay-out of 80p per share in 2020.
Investors will be interested to see the impact of the coronavirus on both drug markers performance over their first three months of trading, though most companies guidance this year is heavily weighted towards the latter half of 2020.
GSK: technical analysis
Shares in GSK have been on a rip of late, with the market valuation gaining 28% since the March lows. The question from here is whether we can sustain this uptrend, as the stock pushes towards the prior peak of £18.25, according to Josh Mahony, senior market analyst at IG.
The short-term outlook will be dictated by the reaction to this confluence of resistance, with the ascending trendline and 76.4% Fibonacci resistance level meeting around £17.08. A break through this inflection point could bring about a bullish continuation signal.
However, given the existence of this current bearish rising wedge pattern, we could see some downside come into play if this zone of resistance is not broken. In particular, if we break below £16.43, things could start taking a more significant bearish turn.
AstraZeneca: technical analysis
AstraZeneca shares have experienced an incredible 41% upside since the March low, with the stock hitting a record high for three-weeks in a row.
This wider weekly chart highlights how significant this move has been, with a standard deviation channel indicating that things could be a little stretched at these levels.
For now we have not seen any bearish intraday signals, yet it could be prudent to be aware of a potential pullback if the short-term picture starts to sour somewhat.
How to trade stocks with IG
Looking to trade GSK and other stocks? Open a live or demo account with IG and buy (long) or sell (short) the asset using derivatives like CFDs in a few easy steps:
Create an IG trading account or log in to your existing account
Enter ‘GlaxoSmithKline’ in the search bar and select it
Choose your position size
Click on ‘buy’ or ‘sell’ in the deal ticket
Confirm the trade
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
See more forex live prices
See more shares live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
See more indices live prices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 20 mins.
